Process on Corporate Responsibility in the field of Pharmaceuticals

Platform on access to medicines in Europe

Capacity Building on Managed Entry Agreements for Innovative Medicines: Meeting on the Terms of Reference

Draft Minutes

Budapest, 4 May 2011, 13h00 – 16h00

Chairs: [redacted]

Participants:

[redacted] DG Enterprise and Industry, European Commission
[redacted], DG Enterprise and Industry, European Commission
[redacted], Belgium
[redacted], Cyprus
[redacted], Czech Republic
[redacted], Denmark
[redacted] Finland
[redacted], Finland
[redacted], France
[redacted], France
[redacted], Hungary
[redacted], Hungary
[redacted], Hungary
[redacted], Italy
[redacted], Italy
[redacted], Italy
[redacted], Latvia
[redacted], Lithuania
[redacted], Malta
[redacted], Malta
[redacted] Netherlands
[redacted] Poland
[redacted], Portugal
[redacted] Spain
[redacted] Slovakia
[redacted] UK
[redacted], Association Internationale de la Mutualité (AIM)
[redacted] European Social Insurance Platform (ESIP)
[redacted], Comité Permanent des Médecins Européens (CPME)
[redacted] European Federation of Pharmaceutical Industries and Associations (EFPIA)
[redacted], (EFPIA)

[redacted] (EGA)
[redacted], European Association of Bioindustries (EuropaBio)y
[redacted] (EuropaBio)
[redacted], Andalusian School of Public Health

Introduction

The Chairs welcomed the participants to the meeting about the project "Capacity Building on Managed Entry Agreements for Innovative Medicines" launched in the framework of the platform *Access to medicines in Europe.*

Presentation of the terms of reference

Italy presented the proposal of terms of references for the project. Each section of the terms of reference was presented in details and discussed among participants.
Comments from participants were collected in order to be included in the final document.

Discussion on the terms of reference

Participants in the meeting raised a number of comments and suggestions .

In particular, it was proposed:

- To highlight in the Objective section that the project is also meant to explore new possibilities and ideas for improvement.

- To include in the Tasks section the administrative and financial resources needed to implement the Managed Entry Agreements at the national level

- To include in the Tasks section that the survey should also be addressed to the industry, in order to represent different stakeholders' perspectives.

- To include in the Tasks section, that comments on Managed Entry Agreements from other stakeholders i.e. patients, health care professionals and industry, will be collected for the SWOT analysis.

- To consider the issue of commercial confidentiality for the disclosure of information on Managed Entry Agreements.

Definition of working groups

Two working groups were defined for the elaboration of the taxonomy and of the survey on a volunteer basis.
Representatives of Belgium, Poland, Spain, EMINET, CPME, Pharmaceutical Industry (EFPIA, EGA, EUOPABIO) will constitute the working group on the taxonomy.

Representatives of the Netherlands, Norway, United Kingdom, EMINET and Pharmaceutical Industry –EFPIA, EGA, EUOPABIOwill constitute the working group on the survey.

Next steps

- Members will receive a final document of the terms of reference and a template for the survey. The next face-to-face meeting was scheduled in Rome at the end of October/beginning of November 2011.

* * *